Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
What’s on the Mind of Margaret “Meg” Murray of the Association for Community Affiliated Plans?
Our guest on this month’s episode of the “What's on Your Mind” podcast is Margaret Murray, M.P.A., founding CEO of the Association for Community Affiliated Plans (ACAP) and a longtime member of Managed Healthcare Executive® editorial advisory board. Murray is an expert on Medicaid and healthcare policies that affect people with low incomes. In the interview with Managing Editor of MHE, Peter Wehrwein, she discusses ACAP’s growth and its legislative wins, Medicaid redetermination, “junk insurance,” and state Medicaid programs carving out pharmacy benefits.
CVS Health, Looking To Up Its Value-based Care Game, Puts Oak Street Health in Its Shopping Cart
The announcement of the $10.6 billion acquisition comes a few months after the company announced it was buying Signify Health, a home health provider, for $8 billion.
For Decades They Went Up and Up. Why Are Liver Cancer Cases and Deaths Now Leveling Off and Possibly Declining?
Testing and effective treatment of hepatitis C with the direct-acting antivirals is the most explanation.
Esophageal Cancer Update
Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.
Rick Bates of RxSense Talks Collab With Mark Cuban's Cost Plus Drugs, Direct-To-Consumer Business and More
In this month’s episode of Tuning In to the C-Suite, Managing Editor Peter Wehrwein talks with Rick Bates, MBA, president and CEO of RxSense. In his conversation with Wehrwein, Bates described RxSense as a “technology platform company that has expertise in the direct-to-consumer business.” He emphasized that RxSense is not a pharmacy benefit manager (PBM) — but, rather, a company that supplies PBMs with technology, including some of the up-and-coming PBMs, such as EmsanaRx and Vivid Clear Rx. Bates and Wehrwein also discussed the Mark Cuban Cost Plus Drug and RxSense launching a standalone business intelligence product called Rx IQ.
After a Slow 2022, Healthcare M&A Poised To Pick Up in 2023, Says Bain
Larger payers have plenty of cash on hand to do deals but will look for “adjacencies” rather than merger and acquisition with other payers because of the regulatory environment, say Bain experts.
Amgen Launches Amjevita, First Humira Biosimilar on the U.S. Market
Amgen says it will sell the first biosimilar to Humira on the U.S. market at two prices.
Insurers Prepare to Fight RADV Rule
The Risk Adjustment Data Validation (RADV) rule was finalized today. The new rule for governing how CMS audits Medicare Advantage plans for overpayment due to inflated risk adjustment could cost insurers billions of dollars.
2 Clarke Drive Cranbury, NJ 08512